MAYINGLONG HEMORRHOIDS- zinc oxide, petrolatum, lanolin ointment
Mayinglong Pharmaceutical Group Co Ltd

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

----------

MAYINGLONG HEMORRHOIDS OINTMENT

Active Ingredients
Zinc Oxide 0.8g Astrigent
Petrolatum 7.85g Protectant

Purpose
Astrigent
Protectant
Protectant

Uses
helps relieve the local itching and discomfort associated with hemorrhoids
temporarily shrinks hemorrhoidal tissue and relieves burning
temporarily provides a coating for relief of anorectal discomforts
temporarily protects the inflamed, irritated anorectal surface to help make bowel movements less painful

Warning
For external and/or intrarectal use only. Not for oral use.

Stop use
bleeding occurs
condition worsens or does not improve within 7 days
introduction of applicator into the rectum causes additional pain

Warning
Apply it carefully during pregnancy.

Warning
Keep this and all drugs out of reach of children.

Direction
Apply properly onto anus or apply on affected areas twice a day.
Other information
Store at 20-25 degree Centigrade (68-77 degree Fahrenheit)

Inactive ingredients
Musk Ketone
Pearl (Hyriopsis Cumming II)
Borneol
Sodium Borate

Drug Facts

store at 20-25 degree Centigrade (68-77 degree Fahrenheit)

inactive ingredients
Musk Ketone
Pearl (Hyriopsis Cumming II)
Borneol
Sodium Borate

Drug Facts

active ingredient

Zinc Oxide (UNII: SOI2LOH54Z) (Zinc Oxide - UNII:SOI2LOH54Z)

Basis of Strength
ZINC OXIDE
Strength
800 mg in 10000 mg

Petrolatum (UNII: 4T6HI2BN9U) (Petrolatum - UNII:4T6HI2BN9U)

Basis of Strength
PETROLATUM
Strength
7850 mg in 10000 mg

Product Information

Product Type
HUMAN OTC DRUG

Route of Administration
TOPICAL

Item Code (Source)
NDC:68511-993-01

MAYINGLONG HEMORRHOIDS
zinc oxide, petrolatum, lanolin ointment

Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZINC OXIDE</td>
<td>ZINC OXIDE</td>
<td>800 mg in 10000 mg</td>
</tr>
<tr>
<td>PETROLATUM</td>
<td>PETROLATUM</td>
<td>7850 mg in 10000 mg</td>
</tr>
</tbody>
</table>

Other information
Store at 20-25 degree Centigrade (68-77 degree Fahrenheit)

Inactive ingredients
Musk Ketone
Pearl (Hyriopsis Cumming II)
Borneol
Sodium Borate

Drug Facts

active ingredient

Zinc Oxide (UNII: SOI2LOH54Z) (Zinc Oxide - UNII:SOI2LOH54Z)

Basis of Strength
ZINC OXIDE
Strength
800 mg in 10000 mg

Petrolatum (UNII: 4T6HI2BN9U) (Petrolatum - UNII:4T6HI2BN9U)

Basis of Strength
PETROLATUM
Strength
7850 mg in 10000 mg

Product Information

Product Type
HUMAN OTC DRUG

Route of Administration
TOPICAL

Item Code (Source)
NDC:68511-993-01

MAYINGLONG HEMORRHOIDS
zinc oxide, petrolatum, lanolin ointment

Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZINC OXIDE</td>
<td>ZINC OXIDE</td>
<td>800 mg in 10000 mg</td>
</tr>
<tr>
<td>PETROLATUM</td>
<td>PETROLATUM</td>
<td>7850 mg in 10000 mg</td>
</tr>
</tbody>
</table>
**Inactive Ingredients**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>MUSK KETONE (UNII: 483V3E.1L6J)</td>
<td></td>
</tr>
<tr>
<td>PEARL (HYRIOPSIS CUMINGII) (UNII: A75L5FZ40U)</td>
<td></td>
</tr>
<tr>
<td>BORNEOL (UNII: M89NIB437X)</td>
<td></td>
</tr>
<tr>
<td>SODIUM BORATE (UNII: 91MBZ81BQO)</td>
<td></td>
</tr>
<tr>
<td>LANOLIN (UNII: 7EV65EAW6H)</td>
<td></td>
</tr>
</tbody>
</table>

**Packaging**

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:68511-993-01</td>
<td>10000 mg in 1 CARTON; Type 0: Not a Combination Product</td>
<td>10/25/2017</td>
<td></td>
</tr>
</tbody>
</table>

**Marketing Information**

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>OTC monograph final</td>
<td>part346</td>
<td>12/15/2003</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Mayinglong Pharmaceutical Group Co Ltd (526823828)

**Registrant** - Mayinglong Pharmaceutical Group Co Ltd (526823828)

**Establishment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayinglong Pharmaceutical Group Co Ltd</td>
<td></td>
<td>526823828</td>
<td>manufacture(68511-993)</td>
</tr>
</tbody>
</table>

Revised: 3/2018